S. Mantuano

发表

Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis

A. la Sala, M. Bisceglia, P. Musto, 2004, Leukemia & lymphoma.

Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.

A. la Sala, M. Boccadoro, T. Guglielmelli, 2006, Leukemia research.

Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study

E. Iannitto, A. Guarini, C. Minoia, 2020, European journal of haematology.

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.

P. Musto, A. Carella, A. Falcone, 2003 .

Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial

A. la Sala, P. Musto, A. Carella, 2003, Leukemia & lymphoma.

Rituximab to treat chronic lymphoproliferative disorder‐associated pure red cell aplasia

A. la Sala, L. Mastrullo, M. Villa, 2009, European journal of haematology.

Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.

P. Musto, A. Carella, A. Falcone, 2004 .

Diffuse B-Large Cell Lymphomas (DBLCL) with Hepatitis-C Virus (HCV) Infection: Clinical Outcome and Preliminary Results of a Pilot Study Combining R-CHOP with Antiviral Therapy.

P. Musto, M. Dell'olio, N. Cascavilla, 2005 .

Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

G. Rossi, A. Carella, A. Falcone, 2012 .